Multi-phase Dual Energy for Quantitative and Radiologic Evaluation of Chronic Liver Disease

Overview

About this study

The purpose of this study is to assess the combined impact of post-processing methods that quantify potential biomarkers of chronic liver disease (AEF, fECS) and that improve iodine signal (vMono+) on detecting liver fibrosis and hepatic masses or esophageal varices, in comparison to routine contrast-enhanced liver CT.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Known or suspected chronic liver disease with or without hepatocellular carcinoma.
  • Informed consent to research contrast-enhanced, dual energy CT and unenhanced MR scan with elatography.
  • Serum creatine, bilirubin and INR ordered for clinical purposes.
  • A negative pregnancy test is required, if the subject is a female of child bearing age

Exclusion Criteria: 

  • Any contraindication for MR imaging (MRI) including pacemakers, cochlear implants, and certain spinal stimulation devices.
  • Insufficient MR image quality for quantitative analysis.
  • A female subject with a positive pregnancy test

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Joel Fletcher, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20309521

Mayo Clinic Footer